Growing the Future of Cancer Research: Inside the Promise of Organoids
Organoids are miniature lab-grown tissues that closely mimic human biology and hold promise for personalizing cancer treatment responses. Their adoption in drug discovery is growing as they offer superior biological relevance over traditional models. Key discussions around organoids include their development, applications, and significance in immuno-oncology.
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Promoted content from Crown Bioscience on MarketScale.
Key takeaways
Organoids mimic human biology more closely than traditional models.
Their superiority is reflected in better prediction of patient-specific drug responses.
The technology is driving innovation across the drug development pipeline.
Get featured
Want to get featured in MarketScale Healthcare?
Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.
In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more standardized and accessible, their use is expanding across the drug development pipeline—from basic biology to clinical trial simulation.
These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses.
But what makes organoids different from tumoroids, and how close are we to seeing them as a new gold standard in immuno-oncology research?
In this episode of CrownCast by Crown BioScience, host Jonny McMichael speaks with Dr. Leo Price, Senior Vice President of Corporate Innovation, about the origin, current applications, and future of organoid models. Together, they explore why organoids are attracting increasing attention from pharma and biotech, the crucial role of stem cell-derived differentiation, and how the platform is reshaping translational and personalized medicine.
Key takeaways from the episode:
- Organoids offer superior biological relevance by preserving the complexity and heterogeneity of patient-derived tissues.
- Clinical studies show high correlation between organoid drug responses and real patient outcomes, boosting confidence in their predictive power.
- The field is advancing rapidly with innovations in high-throughput screening, reagent standardization, and immune-oncology integration.
Dr. Leo Price is a cell biologist with over 20 years of experience in oncology model development. He earned his PhD in cell physiology and completed a postdoctoral fellowship at Scripps Research in California. Before joining Crown BioScience, he served as CEO of OcellO, a pioneer in high-content imaging for 3D cell cultures.
Part of this channel
Crown Bioscience
News, updates, and expert insights from Crown Bioscience.
Your experts belong here
Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.
Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.
About the author
